Moderna (MRNA)
NasdaqMarket Closed
Moderna, Inc. is a biotechnology company built around messenger RNA, or mRNA, medicines. The company became globally known after its COVID-19 vaccine demonstrated the speed and scalability of mRNA technology, moving Moderna from a platform-stage biotech into a commercial vaccine producer.
Moderna continues to apply mRNA across infectious disease, oncology, rare genetic disease and other therapeutic areas. Its research model uses mRNA instructions to direct cells to produce proteins that can trigger immune responses or address disease biology. The company’s pipeline includes multiple clinical programs, and its commercial prospects depend on vaccine demand, new product approvals and the ability to extend mRNA beyond COVID-19. MRNA is therefore both a biotech platform investment and a test of how broadly mRNA medicines can be commercialized.
Last updated
- Market Cap
- $55,449,872,623
- P/E
- —
- P/FCF
- —
- P/S
- 24.89
- Enterprise Value
- $54,323,872,623
- Sector
- Health Care
- Industry
- Biotechnology
- Address
- 325 BINNEY STREET, CAMBRIDGE, MA, 02142
Meta, Nvidia, Intuit, Salesforce, Moderna, Abercrombie, Zoom, and More Stocks That Explain Today’s Market
U.S. State Banking Associations To Launch Blockchain Network
Merck Stock Hits New 52-Week High: What's Driving the Rally?
Review & Preview: Risky Business
TRADING DAY Oil, yields slide
Cancer Vaccine Breakthrough Lifts 5 Biotech Names. Here’s Who’s Best Positioned.
Moderna, Merck Cancer Vax Gives Hope
Thank Moderna for the Healthcare Sector’s Standout Week
Stocks making the biggest moves midday: Moderna, Robinhood, BJ's Wholesale, Coinbase & more
The Dow Jones Industrial Average buys its own bond problem
Stock Market Rally Buckles; Moderna, Gold, Bitcoin Surge While Walmart Tumbles: Weekly Review
Bonds, Cryptos, Moderna Play Havoc With Markets. 2 Reasons for More Chaos.
Pharma Stocks Have Rallied. 2 Stocks to Avoid—and 2 to Buy.
Big, bad bond market
US Stock Market Today: S&P 500 Futures Edge Lower As Higher For Longer Worries Build
TRADING DAY Can't get no relief
Why Moderna (MRNA) Stock Is Trading Lower Today
Stock Market Today: Dow Tumbles 700 Points But Miners Rise; Oil Stocks Catch Fire (Live Coverage)
Morgan Stanley Revamps Merck Stock Target After Cancer Breakthrough
Moderna (MRNA) Stock Looks Stretched With High Growth Already Priced In
- Market Cap
Market cap is the total value of a company's shares, calculated by multiplying the stock price by the number of shares outstanding.
- $55,449,872,623
- Enterprise Value
Enterprise value is the total value of a company, including its market cap, debt, and cash.
- $54,323,872,623
- P/E
P/E ratio compares a company's share price to its earnings per share.
- —
- P/B
P/B ratio compares a company's share price to its book value per share.
- 8.2
- P/S
P/S ratio compares a company's share price to its revenue per share.
- 24.89
- EV / EBITDA
EV/EBITDA measures a company's value compared to its earnings before interest, taxes, depreciation, and amortization.
- -17.64
- EV / Sales
EV/Sales measures a company's value compared to its total revenue.
- 24.38
- EPS
- -7.89
- Dividend Yield
Dividend yield shows how much a company pays in dividends each year compared to its share price.
- 0%
- P/FCF
Price-to-free-cash-flow ratio compares a company's share price to the cash it generates after expenses and investments.
- —
- P/CF
P/CF ratio compares a company's share price to the cash flow it generates from its operations.
- —
- Free Cash Flow
Free cash flow is the cash a company has left after covering operating costs and capital expenses.
- -$1,244,000,000
- ROE
ROE measures how effectively a company uses shareholders' equity to generate profit.
- -46.61%
- ROA
ROA measures how effectively a company uses its assets to generate profit.
- -28.75%
- Debt / Equity
Debt-to-equity ratio compares a company's total debt to its shareholders' equity.
- 0.09
- Current Ratio
Current ratio measures a company's ability to pay short-term debts using its short-term assets.
- 2.29
- Quick Ratio
Quick ratio measures a company's ability to pay short-term debts using cash and other easily available assets.
- 2.18
- Cash
Cash ratio measures a company's ability to cover short-term debts using only cash and cash equivalents.
- 0.68
- Avg Volume
Average volume shows the average number of shares traded over the last 30 trading days, helping indicate liquidity.
- $18,458,387
- Fundamentals Snapshot Price
Fundamentals snapshot price is the stock price used when calculating the company's financial ratios and metrics.
- 138.89
Income Statement
| Line Item | 2026 Q2 | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 |
|---|---|---|---|---|---|
| Revenue | 145M | 389M | 678M | 1.02B | 142M |
| Cost of revenue | 93M | 955M | 452M | 207M | 119M |
| Gross profit | 52M | -566M | 226M | 809M | 23M |
| Operating income | -815M | -1.39B | -857M | -260M | -907M |
| EBITDA | -752M | -1.33B | -790M | -208M | -850M |
| Net income | -782M | -1.34B | -826M | -200M | -825M |
| Income taxes | 15M | 9M | 27M | 13M | 7M |
| Interest expense | -17M | 0 | 0 | 0 | -1M |
| Other operating expenses | 0 | 0 | 0 | 0 | 0 |
| Total operating expenses | 867M | 822M | 1.08B | 1.07B | 930M |
| Basic EPS | -1.97 | -3.4 | -2.11 | -0.51 | -2.13 |
| Diluted EPS | -1.97 | -3.4 | -2.11 | -0.51 | -2.13 |
Balance Sheet
| Line Item | 2026 Q2 | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 |
|---|---|---|---|---|---|
| Total assets | 10.96B | 11.49B | 12.34B | 12.14B | 12.01B |
| Total liabilities | 4.2B | 4.08B | 3.69B | 2.81B | 2.61B |
| Total equity | 6.76B | 7.41B | 8.65B | 9.33B | 9.4B |
| Cash & equivalents | 1.72B | 1.91B | 2.6B | 1.13B | 1.28B |
| Current assets | 5.82B | 5.77B | 6.54B | 6.6B | 6.17B |
| Current liabilities | 2.53B | 2.4B | 1.99B | 1.68B | 1.57B |
| Accounts payable | 167M | 161M | 317M | 267M | 175M |
| Receivables | 17M | 71M | 184M | 1.05B | 36M |
| Inventories | 280M | 146M | 153M | 332M | 240M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Long-term debt | 597M | 603M | 610M | 26M | 32M |
Cash Flow
| Line Item | 2026 Q2 | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 |
|---|---|---|---|---|---|
| Operating cash flow | -526M | -630M | 930M | -847M | -919M |
| Investing cash flow | 329M | -76M | -48M | 700M | 564M |
| Financing cash flow | 14M | 17M | 581M | -1M | 9M |
| Change in cash | -185M | -688M | 1.46B | -147M | -345M |
| Net income | -782M | -1.34B | -826M | -200M | -825M |
| Kind | Filing | Date | Link |
|---|---|---|---|
| edgar index | SCHEDULE 13G — Moderna, Inc. | View Filing | |
| edgar index | 4 — Moderna, Inc. | View Filing | |
| edgar index | SCHEDULE 13G/A — Moderna, Inc. | View Filing | |
| form 4 | Form 4 — Bancel Stephane | View Filing | |
| form 4 | Form 4 — Bancel Stephane | View Filing | |
| form 4 | Form 4 — Bancel Stephane | View Filing | |
| edgar index | 144 — Moderna, Inc. | View Filing | |
| form 4 | Form 4 — Bancel Stephane | View Filing | |
| form 4 | Form 4 — Bancel Stephane | View Filing | |
| form 4 | Form 4 — Bancel Stephane | View Filing | |
| form 4 | Form 4 — Bancel Stephane | View Filing | |
| form 4 | Form 4 — Bancel Stephane | View Filing | |
| form 4 | Form 4 — Bancel Stephane | View Filing | |
| form 4 | Form 4 — Bancel Stephane | View Filing | |
| form 4 | Form 4 — Bancel Stephane | View Filing | |
| form 4 | Form 4 — Bancel Stephane | View Filing | |
| edgar index | 8-K — Moderna, Inc. | View Filing | |
| edgar index | 10-Q — Moderna, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | SCHEDULE 13G/A — Moderna, Inc. | View Filing | |
| edgar index | 4 — Moderna, Inc. | View Filing | |
| edgar index | 144 — Moderna, Inc. | View Filing | |
| form 4 | Form 4 — Hoge Stephen | View Filing | |
| form 4 | Form 4 — Hoge Stephen | View Filing | |
| form 4 | Form 4 — Hoge Stephen | View Filing | |
| form 4 | Form 4 — Hoge Stephen | View Filing | |
| form 4 | Form 4 — Hoge Stephen | View Filing | |
| form 4 | Form 4 — Hoge Stephen | View Filing | |
| form 4 | Form 4 — Hoge Stephen | View Filing | |
| edgar index | 3 — Moderna, Inc. | View Filing | |
| edgar index | 4 — Moderna, Inc. | View Filing | |
| edgar index | 8-K — Moderna, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| form 4 | Form 4 — McDonnell Michael R. | View Filing | |
| form 4 | Form 4 — McDonnell Michael R. | View Filing | |
| form 4 | Form 4 — McDonnell Michael R. | View Filing | |
| edgar index | 4 — Moderna, Inc. | View Filing | |
| edgar index | 4 — Moderna, Inc. | View Filing | |
| form 4 | Form 4 — Banque Soria Ester | View Filing | |
| form 4 | Form 4 — Banque Soria Ester | View Filing | |
| form 4 | Form 4 — Mock James M | View Filing | |
| form 4 | Form 4 — Mock James M | View Filing | |
| form 4 | Form 4 — Mock James M | View Filing | |
| edgar index | 3 — Moderna, Inc. | View Filing | |
| edgar index | 144 — Moderna, Inc. | View Filing | |
| edgar index | 4 — Moderna, Inc. | View Filing | |
| edgar index | 144 — Moderna, Inc. | View Filing | |
| form 4 | Form 4 — Hoge Stephen | View Filing | |
| form 4 | Form 4 — Hoge Stephen | View Filing | |
| form 4 | Form 4 — Hoge Stephen | View Filing | |
| form 4 | Form 4 — Hoge Stephen | View Filing | |
| form 4 | Form 4 — Hoge Stephen | View Filing | |
| form 4 | Form 4 — Hoge Stephen | View Filing | |
| form 4 | Form 4 — Hoge Stephen | View Filing | |
| edgar index | 4 — Moderna, Inc. | View Filing | |
| edgar index | 4 — Moderna, Inc. | View Filing | |
| form 4 | Form 4 — Mock James M | View Filing | |
| form 4 | Form 4 — Mock James M | View Filing | |
| form 4 | Form 4 — Mock James M | View Filing | |
| form 4 | Form 4 — Klinger Shannon Thyme | View Filing | |
| form 4 | Form 4 — Klinger Shannon Thyme | View Filing | |
| form 4 | Form 4 — Klinger Shannon Thyme | View Filing | |
| edgar index | 144 — Moderna, Inc. | View Filing | |
| form 4 | Form 4 — Klinger Shannon Thyme | View Filing | |
| form 4 | Form 4 — Klinger Shannon Thyme | View Filing | |
| form 4 | Form 4 — Klinger Shannon Thyme | View Filing | |
| edgar index | 4 — Moderna, Inc. | View Filing | |
| edgar index | 4 — Moderna, Inc. | View Filing | |
| edgar index | 4 — Moderna, Inc. | View Filing | |
| form 4 | Form 4 — Hoge Stephen | View Filing | |
| form 4 | Form 4 — Hoge Stephen | View Filing | |
| form 4 | Form 4 — Hoge Stephen | View Filing | |
| form 4 | Form 4 — Hoge Stephen | View Filing | |
| form 4 | Form 4 — Hoge Stephen | View Filing | |
| form 4 | Form 4 — Klinger Shannon Thyme | View Filing |